Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB3 in DCD kidney transplantation
NL-OMON22050Not yet recruiting
- Sponsor
- Angion Biomedica Corp.
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in acute kidney failure (AKF) and delayed graft function (DGF) comparing BB3 with Placebo (2 arms). Primary endpoint: Mean difference in creatinine clearance over time. Planned start Dec 2010; status: not yet recruiting.
02
Drugs
terevalefim
03
Conditions
acute kidney failure (AKF)delayed graft function (DGF)
Beyond the preview
Go deeper on NL-OMON22050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22050.